In metastatic renal cell cancer (mRCC) patients treated with targeted therapy, baseline hyponatremia is associated with poorer overall survival (OS), time to treatment failure (TTF), and disease control rate (DCR), according to a study published in European Urology.

Enrolling in a clinical trial has been difficult because Mikaela’s past treatment and need for corticosteroids to control brain swelling are criteria that exclude her from most Phase 2 and Phase 3 trials.